Gilead Sciences (GILD) Dividend Coverage Ratio Growth (1y) (2016 - 2026)
Analysis
Gilead Sciences (GILD) Dividend Coverage Ratio Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 55.87% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -617.59% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -10.85% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.99 Bn | 26.83 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -617.59% |
| Mar 31, 2026 | 49.25% |
| Dec 31, 2025 | 38.87% |
| Sep 30, 2025 | 139.17% |
| Jun 30, 2025 | 19.11% |
| Mar 31, 2025 | 130.90% |
| Dec 31, 2024 | 22.61% |
| Sep 30, 2024 | -43.73% |
| Jun 30, 2024 | 51.62% |
| Mar 31, 2024 | -514.89% |
| Dec 31, 2023 | -15.12% |
| Sep 30, 2023 | 19.06% |
| Jun 30, 2023 | -10.57% |
| Mar 31, 2023 | 7,896.90% |
| Dec 31, 2022 | 323.08% |
| Sep 30, 2022 | -33.01% |
| Jun 30, 2022 | -27.51% |
| Mar 31, 2022 | -99.32% |
| Dec 31, 2021 | -76.70% |
| Sep 30, 2021 | 601.01% |